Cardiorenal benefits of glucagon-like peptide-1 analogues vs. exendin-4 analogues in patients with type 2 diabetes: a meta-analysis based on cardiovascular outcome trials.

Eur J Prev Cardiol · 2022

Last updated 2026-05-28

Journal	Eur J Prev Cardiol, 2022
Citations	1
Relative citation ratio	0.07
NIH percentile	6
Molecules	—
Conditions studied	Type 2 Diabetes, Cardiovascular Risk Reduction, Chronic Kidney Disease

Full record and abstract on PubMed 34939100 ↗